Lena Biosciences

Preclinical Strategies to Reduce Attrition Rates in Drug Discovery Improving attrition rates in drug discovery is critical to making the process more efficient, cost-effective, and successful. There are several strategies and approaches that can help reduce attrition rates: 1. Enhanced Target Validation - Genomic and Proteomic Research: Utilize advanced genomic and proteomic techniques to better understand the biology of disease targets. - CRISPR and RNA Interference: Use gene-editing tools to validate target involvement in disease pathways. - Bioinformatics: Leverage computational models to predict target-drug interactions and off-target effects. 2. Optimized Lead Selection - High-Throughput Screening (HTS): Implement HTS to rapidly identify promising lead compounds. - Structure-Based Drug Design: Use structural biology techniques, such as X-ray crystallography and NMR, to design drugs that precisely interact with targets. - Computational Chemistry: Employ in silico methods to predict pharmacokinetic and pharmacodynamic properties. 3. Improved Predictive Modeling - Machine Learning and AI: Utilize machine learning algorithms to predict drug efficacy and safety profiles. - Big Data Analytics: Analyze large datasets to identify patterns and correlations that can inform drug development. - In Silico Toxicology: Predict potential toxic effects using computational models. 4. Better Preclinical Models - Humanized Preclinical Models: Develop and implement preclinical models that better mimic human physiology and disease. - Organoids and Tissue Chips: Use 3D cultures and organ-on-a-chip technology to study drug effects in more human-like environments. - Advanced Imaging Techniques: Implement sophisticated imaging methods to monitor drug effects in real time. By integrating these strategies early on, pharmaceutical companies may be able to improve the success rates of their drug candidates, ultimately leading to more effective and safer therapies reaching the market. Small companies with their power to innovate may pave the way for new technologies and AI / machine learning approaches and may thus play a critical role in the efforts to come to innovative medicines which are urgently needed for many patients. #pharma #drugdiscovery Kantify Lena Biosciences PhenoVista Elsevier

This is a nice local newspaper article which is pointing to a general dilemma when talking about non-animal methods in regulatory processes. For understandable ethical and humane reasons animal rights groups have petioned the FDA to move faster in approving non-animal testing. On the other side the FDA, while supporting industry efforts to develop and use alternative methods, needs evidence that their regulatory decisions, i.e. the benefit-risk assessment for new drug candidates, can in fact be based on such novel methods. In this context, it is important to note that the FDA Modernization Act 2.0, passed in 2022, freed the FDA from requiring animal tests, i.e. it gave the FDA the option to accept non-animal tests, but didn’t explicitly require FDA to give them priority. To speed up the process, an updated version, the FDA Modernization Act 3.0, is now going further by requiring FDA to establish a process to qualify the new testing methods and expedite drug applications that incorporate non-animal approaches. The updated bill is expected to facilitate the development, qualification, and adoption of testing methods that could reduce or possibly even replace the use of animals in nonclinical testing. From my perspective it is important to note that the FDA Modernization Act 3.0 makes it clear from the very beginning that the reduction and replacement of animals must not be seen as an isolated or independent target in nonclinical research but that there is in fact a high need to improve the predictivity of nonclinical testing methods and to reduce the development time for a biological product or other drug. The low likelyhood of technical success remains the biggest challenge for all R&D organizations in pharmaceutical industry but there is hope that novel (non-animal) technologies along with artificial intelligence/machine learning approaches may lead to better predictions and thereby better outcomes for patients which must be the most important and ultimate goal of any activity. A full alignment and full support from all stakeholders is needed to make this happen. While it is clear that it may still take some time and huge efforts before novel alternative methodologies can be used to fully replace an intact organism, the use of such models to answer a particular question can already be justified now. I am convinced that regulators are open for such discussions. In this context it is encouraging to see that small companies like Lena Biosciences with their power to innovate are offering already now solutions to particular questions and on the long run they may play an important role in the transformation process. Jelena Vukasinovic James T Shoemaker Lena Biosciences

Our next webinar is less than 1 week away! The next webinar in the 3RC & IQ-MPS 2024 webinar series will include presentations on neuromuscular & fibrosis MPS. We are excited to host presentations from 8 companies: AlveoliX, BiomimX, CN Bio, Curi Bio, Hesperos, Mimetas, Newcells Biotech & InSphero. It is not too late to register! Visit the link here: https://lnkd.in/e54TGvDP

𝐁𝐞𝐲𝐨𝐧𝐝 𝐭𝐡𝐞 𝐏𝐞𝐭𝐫𝐢 𝐃𝐢𝐬𝐡: 𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝟑𝐃 𝐂𝐞𝐥𝐥 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟑𝟑 3D cell culture is a type of cell culture that uses three-dimensional (3D) scaffolds to support cell growth and proliferation. 3D cell culture systems provide a more physiologically relevant environment for cells to grow and proliferate in vitro, as compared to two-dimensional (2D) cell culture systems. 3D cell culture systems can be used to study a variety of cell types, including cancer cells, stem cells, and organoids. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗦𝗮𝗺𝗽𝗹𝗲:https://lnkd.in/dDRaacsJ 𝐏𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝟑𝐃 𝐂𝐞𝐥𝐥 𝐂𝐮𝐥𝐭𝐮𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 REPROCELL PromoCell Thermo Fisher Scientific Lonza Avantor 3D Biotek, LLC InSphero Lena Biosciences CN Bio #3DCellCulture #TissueEngineering #BiomedicalResearch #CellularMicroenvironments #Organoids #StemCellCulture #RegenerativeMedicine #LabOnAChip #SpheroidCulture #PrecisionMedicine

Come hear our CEO, Jelena Vukasinovic, The Entrepreneurial Hour Wednesday 1/10/24 at 8 am https://lnkd.in/dRqYU6h James T Shoemaker Eckhard von Keutz Mert Sahin, PhD Charles (Chuck) Kaucher Michael Holland Scott Wold #Startups #entrepreneurs #ATDC

Come hear our CEO, Jelena Vukasinovic, The Entrepreneurial Hour Wednesday 1/10/24 at 8 am https://lnkd.in/dRqYU6h James T Shoemaker Eckhard von Keutz Mert Sahin, PhD Charles (Chuck) Kaucher Michael Holland Scott Wold #Startups #entrepreneurs #ATDC